Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12206769 | 1.00 | FASN (0.36) | FASNMTNR1AMTNR1BPIK3CDEPHX2 | |
| SCHEMBL12207205 | 1.00 | FASN (0.36) | FASNMTNR1AMTNR1BPIK3CDEPHX2 | |
| SCHEMBL20697001 | 0.85 | EPHX2 (0.43) | FASNMTNR1AMTNR1BPIK3CDEPHX2 | |
| SCHEMBL20696892 | 0.85 | EPHX2 (0.43) | FASNMTNR1AMTNR1BPIK3CDEPHX2 | |
| SCHEMBL20696887 | 0.85 | EPHX2 (0.43) | FASNMTNR1AMTNR1BPIK3CDEPHX2 | |
| SCHEMBL20697000 | 0.85 | EPHX2 (0.43) | FASNMTNR1AMTNR1BPIK3CDEPHX2 | |
| SCHEMBL18347977 | 0.85 | EPHX2 (0.43) | FASNMTNR1AMTNR1BPIK3CDEPHX2 | |
| SCHEMBL23010716 | 0.84 | KDM5A (0.33) | EPHX2GRM7SMYD3ATMKDM5A | |
| SCHEMBL22906171 | 0.84 | KDM5A (0.33) | EPHX2GRM7SMYD3ATMKDM5A | |
| SCHEMBL22906172 | 0.84 | KDM5A (0.33) | EPHX2GRM7SMYD3ATMKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586956-B2 | Isoquinoline and naphthyridine derivatives | GENENTECH, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586956-B2 | Isoquinoline and naphthyridine derivatives | GENENTECH, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20140343036-A1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | GENENTECH, INC. (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343036-A1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | NQO1, NDUFC2, NDUFV2 | FASN 1561/4885MTNR1A 1696/4885MTNR1B 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.